financetom
Business
financetom
/
Business
/
Washington Federal Q3 EPS beats expectations on improved margins
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Washington Federal Q3 EPS beats expectations on improved margins
Jul 17, 2025 2:34 PM

Overview

* Washington Federal fiscal Q3 EPS of $0.73 beats analyst expectations, per LSEG data

* Net interest income rises to $168 mln, driven by improved margins

* Co repurchased 1.66 mln shares during quarter

Outlook

* Company notes tepid loan demand amid economic uncertainty

* Washington Federal anticipates continued cautious borrower behavior

Result Drivers

* IMPROVED MARGINS - Strong core earnings driven by improved net interest margin

* COST REDUCTION - Decreased cost of funds due to lower deposit rates and reduced borrowings

* SHARE REPURCHASE - Aggressive share repurchase contributed to EPS increase and tangible book value growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Beat $0.73 $0.68 (4

Analysts

)

Q3 Net $168 mln

Interest

Income

Q3 Net 2.7%

Interest

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for WaFd Inc ( WAFD ) is $29.50, about 0.2% above its July 16 closing price of $29.45

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study
Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study
Jun 26, 2024
11:15 AM EDT, 06/26/2024 (MT Newswires) -- Repare Therapeutics ( RPTX ) said Wednesday that initial data from a phase one study of lunresertib, or RP-6306, combined with Folfiri showed promising efficacy and tolerability in patients with advanced solid tumors. The data helped identify the preliminary recommended phase 2 dose of 60 milligrams lunresertib twice a day with standard Folfiri,...
Bell Canada, Best Buy, Launch Best Buy Express, Will Open 167 Stores
Bell Canada, Best Buy, Launch Best Buy Express, Will Open 167 Stores
Jun 26, 2024
11:15 AM EDT, 06/26/2024 (MT Newswires) -- BCE's (BCE.TO) Bell Canada unit and Best Buy Canada, said Wednesday they formed a strategic partnership to introduce 167 small-format consumer-technology retail stores across Canada. The stores will be branded Best Buy Express. The inaugural Best Buy Express store has opened in Guildford Town Centre, Surrey, B.C. Customers can shop Best Buy's full...
What's Going On With Carnival Stock?
What's Going On With Carnival Stock?
Jun 26, 2024
Carnival Corporation ( CCL ) shares are trading higher Wednesday after the company posted better-than-expected second-quarter financial results Tuesday.  The Details: Carnival's stock notched its best trading day of 2024 Tuesday after the company beat analysts' expectations on both the top and bottom line. The company said it continues to experience strong bookings momentum driven by record booking volumes for...
Cyclacel Receives Notice of European Patent Grant for  Plogosertib; Shares Rise
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise
Jun 26, 2024
11:17 AM EDT, 06/26/2024 (MT Newswires) -- Cyclacel Pharmaceuticals ( CYCC ) said Wednesday the European Patent Office has notified the company of its intention to grant a patent for plogosertib, which is being studied for cancer treatment. The patent covers claims to pharmaceutical compositions of the PLK1 inhibitor and supports a switch to a new oral formulation with improved...
Copyright 2023-2026 - www.financetom.com All Rights Reserved